BC Cancer’s Personalized OncoGenomics (POG) Program is a world-leading initiative applying whole-genome and transcriptome analysis (WGTA) to inform real-time treatment decisions for patients with advanced, hard-to-treat cancers. Using a mixed methods approach, Dr. Regier’s CCR research lab PACER is estimating the clinical effectiveness and cost-effectiveness of WGTA compared to standard care with a view to support POG program optimization.
Key articles: Weymann D, Laskin J, Roscoe R, Schrader K, Chia S, Yip S, Cheung W, Gelmon K, Karsan A, Renouf D et al: The cost and cost trajectory of whole-genome analysis guiding treatment of patients with advanced cancers. Molecular Genetics & Genomic Medicine 2017. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441418/